Danaher Corporation
Moat Score — Danaher Corporation
Total Moat Score
19 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Danaher owns a portfolio of well-regarded life-science and diagnostics brands (Cytiva, Beckman Coulter, Leica, Cepheid) backed by patents, FDA/regulatory clearances, and deep technical know-how accumulated across decades of specialized instrument development. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 3 / 5 | The proprietary Danaher Business System gives management a repeatable playbook for cutting waste and expanding margins after each acquisition, providing a genuine, process-driven cost advantage over less disciplined peers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | Recurring, mission-critical consumables and reagents sold into regulated biopharma and clinical-lab workflows support strong pricing power, though public scrutiny over Cepheid's diagnostic cartridge pricing shows this power has limits and reputational risk. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Danaher's instruments and consumables businesses do not become more valuable to one customer as more customers adopt them — there is no network effect in life-science tools and diagnostics. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 5 / 5 | The classic razor-and-blade model — instruments that require Danaher-specific consumables, reagents, and software, often validated into regulated biomanufacturing and clinical workflows — makes switching costly, slow, and risky for customers, producing very high retention. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | Life-science tools and diagnostics are served by a small set of large, diversified players (Danaher, Thermo Fisher, Agilent, Roche, Abbott); the R&D, regulatory, and distribution scale required to compete broadly discourages casual new entrants, though niche competitors persist. |